Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles (Q40821392)

24 September 2017

Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles (English)

1 reference

24 September 2017

1 reference

8

Peter van der Ley

0 references

author name string

Merijn L M Salverda

1

1 reference

24 September 2017

Sanne M Meinderts

2

1 reference

24 September 2017

Hendrik-Jan Hamstra

3

1 reference

24 September 2017

Alex Wagemakers

4

1 reference

24 September 2017

Joppe W R Hovius

5

1 reference

24 September 2017

Arno van der Ark

6

1 reference

24 September 2017

Michiel Stork

7

1 reference

24 September 2017

Peter van der Ley

8

1 reference

24 September 2017

language of work or name

English

0 references

publication date

19 January 2016

1 reference

24 September 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

24 September 2017

34

1 reference

24 September 2017

8

1 reference

24 September 2017

1025-1033

1 reference

Virulence and immunomodulatory roles of bacterial outer membrane vesicles

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Delivery of foreign antigens by engineered outer membrane vesicle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Outer membrane vesicles as acellular vaccine against pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Bexsero: a multicomponent vaccine for prevention of meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Bacterial outer membrane vesicles and vaccine applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Incorporation of Heterologous Outer Membrane and Periplasmic Proteins into Escherichia coli Outer Membrane Vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Engineered bacterial outer membrane vesicles with enhanced functionality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Immunity to intracellular Salmonella depends on surface-associated antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

The delicate balance in genetically engineering live vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Positional assembly of enzymes on bacterial outer membrane vesicles for cascade reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Expressing genes in different Escherichia coli compartments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Recombinant outer membrane vesicles to augment antigen-specific live vaccine responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Extracellular production of recombinant proteins using bacterial autotransporters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

The autodisplay story, from discovery to biotechnical and biomedical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Surface display of Zymomonas mobilis levansucrase by using the ice-nucleation protein of Pseudomonas syringae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Induction of direct antimicrobial activity through mammalian toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Design and development of a novel vaccine for protection against Lyme borreliosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Protection of mice against the Lyme disease agent by immunizing with recombinant OspA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Lipoprotein sorting in bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Identification of an outer membrane protein required for the transport of lipopolysaccharide to the bacterial cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Essential role for OspA/B in the life cycle of the Lyme disease spirochete

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Probing the Borrelia burgdorferi surface lipoprotein secretion pathway using a conditionally folding protein domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Surface-displayed viral antigens on Salmonella carrier vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Lipoproteins of bacterial pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Translocation of Borrelia burgdorferi surface lipoprotein OspA through the outer membrane requires an unfolded conformation and can initiate at the C-terminus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Borrelia burgdorferi lipoproteins are secreted to the outer surface by default.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Identification of a common immune signature in murine and human systemic Salmonellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.019

10.1016/J.VACCINE.2016.01.019

7 January 2021

Identifiers

DOI

1 reference

24 September 2017

1 reference